Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

American Academy of Neurology Annual Meeting
B1 cells are unaffected by immune modulatory treatment in remitting-relapsing multiple sclerosis patients.
Biogen Idec's TECFIDERA™ (dimethyl fumarate) approved in US as a first-line oral treatment for multiple sclerosis
“Human Medicines” page
Rituximab does not reset defective early B cell tolerance checkpoints.
MS Frontiers 2015
Changes in Blood B Cell-Activating Factor (BAFF) Levels in Multiple Sclerosis: A Sign of Treatment Outcome.
Immunology 2015
Autoantibodies and pain.
Randomized trial of oral teriflunomide for relapsing multiple sclerosis.
Checklist for reporting and reviewing studies of experimental animal models of multiple sclerosis and related disorders.
Biogen Data at 2016 AAN Annual Meeting Highlight Its Expansive Portfolio of MS Therapies That Meets Diverse Needs of Patients
Oxidative stress is differentially present in multiple sclerosis courses, early evident, and unrelated to treatment.
Remyelination of the superior cerebellar peduncle in the mouse following demyelination induced by feeding cuprizone.
A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis.
Episode 26 with Dr. Tim Kennedy on remyelination and oligodendrocyte development
Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial.
Gene Expression Profiles of Autophagy-Related Genes in Multiple Sclerosis.
Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study.
Dimethyl fumarate attenuates experimental autoimmune neuritis through the nuclear factor erythroid-derived 2-related factor 2/hemoxygenase-1 pathway by altering the balance of M1/M2 macrophages.
T-helper 1-type immunity to trophoblast in women with recurrent spontaneous abortion.
Long-term persistence with injectable therapy in relapsing-remitting multiple sclerosis: an 18-year observational cohort study.
Activity-Dependent and Experience-Driven Myelination Provide New Directions for the Management of Multiple Sclerosis.
Dimethylfumarate Impairs Neutrophil Functions.
Interrater Reliability of Four Sensory Measures in People with Multiple Sclerosis.

Pages